Non-invasive prenatal testing market size, share and trends analysis report by pregnancy period, by pregnancy risk, by method, by technology, by product, by application, by end use, by region and sector forecast, 2022

ReportLinker

ReportLinker

Non-invasive prenatal testing market size, share and trends analysis report by pregnancy period, by pregnancy risk, by method, by technology, by product, by application, by end use, by region, and sector forecast, 2022 – 2030

NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of “Non-invasive prenatal testing market size, trend analysis report and shares by period of pregnancy, by pregnancy risk, by method, by technology, by product, application, and use” Final, Region and Sector Outlook, 2022 – 2030″ – https://www.reportlinker.com/p06318486/?utm_source=GNW

Trends and growth of the non-invasive market for prenatal tests

The global market size for non-invasive prenatal tests is expected to reach $7.71 billion by 2030. It is expanding at a compound annual growth rate of 9.61% from 2022 to 2030. The increased incidence of chromosomal abnormalities is expected to accelerate the growth of the market. Among all the countries, there is a great opportunity in China for non-invasive prenatal screening, with nearly 14.65 million annual births and an increasing number of high-risk pregnancies.

In addition, India has a heavy burden of genetic diseases, with various studies indicating chromosomal abnormalities at a rate of 1 in 166 newborns in the country, while the incidence of trisomy 21 (Down syndrome) is as high as 1 in 800 births. . This results in 32,000 newborns born with Down syndrome each year.

Families can benefit from early and accurate screening using NIPT to identify the genetic problem of their child. Thus, this high infection rate is expected to increase the demand for prenatal testing.

With the closures due to COVID-19, NIPT has gained attention because it provides high-accuracy screening with minimal risk of infection compared to invasive procedures such as chorionic villus sampling and amniocentesis, both of which may require hospitalization and put patients and medical professionals at risk of contracting COVID – 19 infection. Furthermore, there has been a growing demand for prescriptions of non-prescription drugs; However, it has been limited to fewer qualified people due to the lack of infrastructure and adoption of telemedicine facilities in most countries.

The reimbursement scenario related to non-surgical prenatal testing is highly variable, however, government support and favorable insurance policies are boosting market growth.

For example, in the Netherlands, prenatal tests are fully reimbursed in the second trimester, which increases the adoption of these tests. Increased government initiatives to encourage the bio- and pharmaceutical industry in emerging economies such as India and China are expected to increase the demand for non-invasive prenatal testing solutions and services.

Major market players focus on developing new products to enhance their product portfolios and offer innovative products to customers, and in March 2020, Agilent Technologies launched three new microarrays to support prenatal and postnatal research by cytogenetics laboratories.

Probes on cell microarrays provide high-resolution detection of copy number change and loss of copy-neutral heterozygosity associated with neuropsychiatric disorders, developmental delay, intellectual disability, and congenital anomalies in constitutional DNA samples.

Highlights of the Non-Invasive Prenatal Testing Market Report:
• By pregnancy, 13-24 weeks dominate the market in 2021 due to the maximum number of non-surgical prenatal procedures performed in the second trimester.
• The low-risk pregnancy segment is expected to witness significant growth during the forecast period. Government support such as budget allocation for medium-risk pregnancies contributed to the growth of the sector
• Depending on the product, CST in the maternal plasma testing segment accounted for the largest share of revenue in 2021. The use of CST in predicting the risk of genetic disorders in prenatal care through various genetic analyses is increasing.
• The Asia Pacific region is expected to witness the highest compound annual growth rate during the forecast period. Higher maternal age and improved healthcare infrastructure are likely to boost market growth
• North America dominated the market in 2021 due to high R&D investments, advanced healthcare facilities, and whole genome sequencing development
Read the full report: https://www.reportlinker.com/p06318486/?utm_source=GNW

Around Reportlinker
ReportLinker is an award winning market research solution. Reportlinker finds and organizes the latest industry data so you have all the market research you need – instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Leave a Comment